ABBV vs. MRNA: AbbVie vs. Moderna Stock Comparison

November 11, 2026

How do AbbVie (ABBV) and Moderna (MRNA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) and Moderna (MRNA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for AbbVie (ABBV) and Moderna (MRNA)
Profile Item	ABBV	MRNA
Name	AbbVie Inc.	Moderna Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	514.92 billion USD	101.48 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	January 2, 2013	December 7, 2018
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ABBV

MRNA

GSPC

AbbVie (ABBV) vs. Moderna (MRNA), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for AbbVie (ABBV) and Moderna (MRNA). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for AbbVie (ABBV) and Moderna (MRNA). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and Moderna (MRNA)
Metric	ABBV	MRNA
Total Return (1Y)	37.33%	1,031.66%
Total Return (3Y, Annualized)	32.74%	58.68%
Total Return (5Y, Annualized)	24.73%	3.23%

Risk Profile

Drawdown History

ABBV

MRNA

GSPC

AbbVie (ABBV) vs. Moderna (MRNA), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for AbbVie (ABBV) and Moderna (MRNA). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AbbVie (ABBV) and Moderna (MRNA)
Metric	ABBV	MRNA
Volatility (1Y, Annualized)	25.65%	194.88%
Beta (5Y)	0.21	1.08
Max Drawdown (5Y)	-21.92%	-93.93%
Avg. Volume (3M)	4.76M	21.61M

Risk-Adjusted Performance

Risk-Return Positioning

ABBV and MRNA are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and Moderna (MRNA)
Metric	ABBV	MRNA
Sharpe Ratio (1Y)	1.29	5.27
Sortino Ratio (1Y)	2.02	20.44

Profitability

ROE (TTM)

AbbVie (ABBV) has no ROE value reported for this period; Moderna (MRNA) reports a negative figure of -39.00%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
ABBV: --

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.00%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
MRNA: -39.00%
Q1: -64.05%
Min: -167.77%

AbbVie (ABBV) vs. Moderna (MRNA): ABBV does not report ROE, so it has no value marker; MRNA is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile AbbVie (ABBV) reports 15.67%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max: 18.05%
ABBV: 15.67%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-141.43%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%
MRNA: -141.43%

AbbVie (ABBV) vs. Moderna (MRNA): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile AbbVie (ABBV) reports 39.59%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max: 83.12%
ABBV: 39.59%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-557.93%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%
MRNA: -557.93%

AbbVie (ABBV) vs. Moderna (MRNA): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and Moderna (MRNA)
Metric	ABBV	MRNA
ROE (TTM)	--	-39.00%
ROA (TTM)	10.74%	-13.26%
Net Margin (TTM)	15.67%	-141.43%
Operating Margin (TTM)	39.59%	-557.93%
Gross Margin (TTM)	73.72%	-66.02%

Growth

Revenue Growth

AbbVie (ABBV) at 8.57% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.

AbbVie (ABBV) vs. Moderna (MRNA): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: AbbVie (ABBV) reports EPS growth of -0.84%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.

AbbVie (ABBV) vs. Moderna (MRNA): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AbbVie (ABBV) and Moderna (MRNA)
Metric	ABBV	MRNA
Revenue Growth (YoY)	8.57%	-39.92%
Revenue Growth (3Y CAGR)	1.75%	-53.30%
EPS Growth (YoY)	-0.84%	--
EPS Growth (3Y CAGR)	-29.03%	--

Financial Strength

Current Ratio (MRQ)

Both AbbVie (ABBV) at 0.87 and Moderna (MRNA) at 2.30 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ABBV: 0.87
Min: 0.10

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.30

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MRNA: 2.30
Min: 0.10

AbbVie (ABBV) vs. Moderna (MRNA): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Moderna (MRNA) carries debt-to-equity ratio of 0.19 against its industry range, while AbbVie (ABBV) reports no figure this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
ABBV: --

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max: 1.42
Q3: 0.65
MRNA: 0.19
Median: 0.15
Q1: 0.02
Min: 0.00

AbbVie (ABBV) vs. Moderna (MRNA): ABBV does not report debt-to-equity ratio, so it has no value marker; MRNA is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and Moderna (MRNA)
Metric	ABBV	MRNA
Current Ratio (MRQ)	0.87	2.30
Debt / Equity (MRQ)	--	0.19
Net Debt / EBITDA	2.21	--

Dividends

Dividend Yield (TTM)

Moderna (MRNA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV: 2.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Moderna (MRNA): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Moderna (MRNA) pays no dividend (payout 0.00%).

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV: 117.35%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Moderna (MRNA): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and Moderna (MRNA)
Metric	ABBV	MRNA
Dividend Yield (TTM)	2.40%	0.00%
Dividend Payout Ratio (TTM)	117.35%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: AbbVie (ABBV) trades at 50.05 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max: 85.34
ABBV: 50.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
MRNA: --

AbbVie (ABBV) vs. Moderna (MRNA): MRNA does not report P/E ratio, so it has no value marker; ABBV is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

AbbVie (ABBV) at 7.80 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max: 58.18
Q3: 25.77
ABBV: 7.80
Median: 7.30
Q1: 3.01
Min: 0.01

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.55

Max: 58.18
MRNA: 45.55
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

AbbVie (ABBV) vs. Moderna (MRNA): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Moderna (MRNA) reports 11.58, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
ABBV: -112.34

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.58

Max: 13.53
MRNA: 11.58
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

AbbVie (ABBV) vs. Moderna (MRNA): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and Moderna (MRNA)
Metric	ABBV	MRNA
P/E Ratio (TTM)	50.05	--
P/S Ratio (TTM)	7.80	45.55
P/B Ratio (MRQ)	-112.34	11.58
Free Cash Flow Yield (TTM)	3.44%	0.29%